



Significant clinical outcomes and survivorship achieved for unicompartmental knee arthroplasty (UKA) using JOURNEY[®] II UK

D’Amario F, De Berardinis L, Zanon G, Qordja F, Vitale U, Pompilio Gigante A. First Italian experience with the oxinium metal-backed fixed-bearing medial Journey II Unicompartmental Knee System: promising short-term outcomes of 145 cases. *J Clin Med.* 2024;13(5):1303.

Available at: [Journal of Clinical Medicine](#)  

Key points

For patients undergoing UKA with JOURNEY II UK at 24 months:



Significant improvements
in multiple **performance outcomes** from baseline
($p < 0.0001$)



Patient satisfaction
scored **highly**
(9.32/10)



No patients
experienced **complications**
or required **revision surgery**

Overview

- Single centre, single non-developer surgeon, retrospective study of patients undergoing medial UKA with JOURNEY II UK in Italy
 - 145 patients undergoing surgery between December 2020 and December 2021 with minimum 2-year follow-up
- The Forgotten Joint Score-12 (FJS-12) was calculated at 12 and 24 months, and patient satisfaction was collected at 24 months
- The following outcomes were assessed preoperatively and post-operatively at 12 and 24 months:
 - Knee Society Knee Score (KSKS)
 - Knee Society Function Score (KSFS)
 - Oxford Knee Society (OKS) score
 - University of California Los Angeles Activity Score (UCLA)
 - Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS)
 - SF-36 Mental Component Summary (MCS)

Results

- Significant improvement in several clinical outcome measures recorded pre-operatively, and at 12 months and 24 months (Table)
- Improvement in FJS-12 from 12 months to 24 months (83.05 vs 85.41; $p = ns$)
- Patient satisfaction scored highly at 24 months (9.32/10)
- No patients experienced complications or required revision surgery
- All patients returned to sport practice

Table. Clinical outcomes achieving significant improvement during follow-up

Outcome	Pre-operative mean	12 months mean	24 months mean	P value
KSKS	44.55	87.79	89.53	<0.0001
KSFS	54.83	88.44	90.99	<0.0001
OKS	38.57	25.01	20.29	<0.0001
UCLA	5.03	6.39	7.48	<0.0001
SF-36 PCS	31.75	41.17	49.94	<0.0001
SF-36 MCS	46.13	52.70	56.38	<0.0001

Conclusions

Unicompartmental knee arthroplasty of 145 patients using JOURNEY II UK showed excellent survival rates at two years (100%), in addition with good-to-excellent clinical outcomes, 100% return to sports and high patient satisfaction.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, warnings and precautions, please consult the product's Instructions for Use (IFU) prior to use.